ad image

Company Info

Takeda

Takeda

Drug Discovery & Development

Overview

Takeda's contract manufacturing division creates products for more than 50 external clients. The company's manufacturing facilities operate in strict compliance with current good manufacturing practices (cGMP). Takeda attributes its success in contract manufacturing to its customer-tailored approach and quality standards, which are aligned with regulatory authorities in the United States, Europe, Japan, South and Central America and other regions. Takeda provides lifecycle support that includes clinical development, product launch, packaging, process optimization and formulation.
Takeda
Contributions
17 Contributions1 / 1
Takeda
Cell Therapy Capacity

Takeda Opens New R&D Cell Therapy Manufacturing Facility to Support Expansion of Next-Generation Clinical Programs

Takeda

PR-M09-20-NI-17-1291Sep 15, 2020
Takeda
Sales

Takeda to Sell OTC Drug Unit to Blackstone for $2.3bn

Takeda

PR-M08-20-NI-33Aug 19, 2020
Takeda
Drug Development

Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders

Takeda

PR-M06-20-NI-019Jun 16, 2020
Takeda
Licensing Agreement

ProThera Biologics and Takeda Develop Novel Plasma-Derived Therapy Based on Inter-alpha Inhibitor Proteins

Takeda

PR-M04-20-NI-034Apr 24, 2020
Takeda
Recall

Takeda Issues US Recall of Two Lots of VONVENDI

Takeda

PR-M02-20-NI-038Feb 27, 2020
Takeda
Diagnostics

Takeda and Enzyre to Develop Diagnostic Device Allowing Hemophilia Patients to Determine their Coagulation Status at Home

Takeda

PR-M12-19-NI-009Dec 06, 2019
Takeda
Divest

Takeda Agrees to Divest Select OTC and Non-core Assets to Acino for Over $200 Million USD

Takeda

PR-M10-19-NI-021Oct 15, 2019
Takeda
CSR

Takeda Selects Five New Partnerships for Annual Global Corporate Social Responsibility (CSR) Program

Takeda

PR-M07-19-NI-008Jul 05, 2019
Takeda
Collaboration

Takeda and Frazier Healthcare Partners Announce Collaboration to Launch Phathom Pharmaceuticals

Takeda

PR-M05-19-NI-058May 21, 2019
Takeda
Announcement

Takeda Opens New Global Research Center in San Diego

Takeda

PR-M05-19-NI-010May 03, 2019
Takeda
Real World Data

New Real-World Data Analyses Support the Long-Term Use of Entyvio® (vedolizumab) in Bio-Naïve Patients for the Treatment of Moderate to Severe Ulcerative Colitis or Crohn's Disease

Takeda

PR-M10-18-NI-034Oct 10, 2018
Takeda
Phase III Trial

Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint Demonstrating Superiority in Progression-Free Survival Versus Crizotinib

Takeda

PR-M07-18-NI-094Jul 27, 2018
Takeda
Prescribing Information

TRINTELLIX® Prescribing Information Now Includes New Data Showing Improvement in Processing Speed

Takeda

PR-M05-18-NI-027May 08, 2018
Takeda
Clinical Data

Takeda Announces Publication of Final Data from ICLUSIG® (ponatinib) Pivotal Phase 2 PACE Trial in Blood

Takeda

PR-M03-18-NI-089Mar 26, 2018
Takeda
Innovation

Takeda Announces Publication of Study Utilizing State-of-the-Art Modeling to Better Understand Optimal Treatment Positioning for Patients with Ulcerative Colitis

Takeda

PR-M02-18-NI-042Feb 13, 2018
Takeda
Vaccine

Takeda’s Zika Vaccine Candidate Receives U.S. FDA Fast Track Designation

Takeda

PR-M02-18-NI-003Feb 01, 2018
Takeda

Takeda and Denali Therapeutics Collaborate to Develop and Commercialize Therapies for Neurodegenerative Diseases

Takeda

PR-M01-18-NI-015Jan 08, 2018
1 / 1
0 Contributors1 / 0

No authors found

1 / 0